Enzyme-activated nanoconjugates for tunable release of doxorubicin in hepatic cancer cells

Medina, Scott H.; Chevliakov, Maxim V.; Tiruchinapally, Gopinath; Durmaz, Yasemin Yüksel; El-Sayed, Mohamed

doi:10.1016/j.biomaterials.2013.02.070

Cited by 82 publications

(62 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of cleavage controls the drug release kinetics (Kopeček, 1984). Enzymatically cleavable drug-polymer conjugates may be used for target-specific drug delivery, if the enzyme is concentrated in target tissues (Medina et al, 2013). …”

Section: Drug Release Mechanismsmentioning

confidence: 99%

Controlled drug release from pharmaceutical nanocarriers

Lee

Yeo

2015

Chemical Engineering Science

420

240

View full text Add to dashboard Cite

Nanocarriers providing spatiotemporal control of drug release contribute to reducing toxicity and improving therapeutic efficacy of a drug. On the other hand, nanocarriers face unique challenges in controlling drug release kinetics, due to the large surface area per volume ratio and the short diffusion distance. To develop nanocarriers with desirable release kinetics for target applications, it is important to understand the mechanisms by which a carrier retains and releases a drug, the effects of composition and morphology of the carrier on the drug release kinetics, and current techniques for preparation and modification of nanocarriers. This review provides an overview of drug release mechanisms and various nanocarriers with a specific emphasis on approaches to control the drug release kinetics.

show abstract

Section: Drug Release Mechanismsmentioning

confidence: 99%

Controlled drug release from pharmaceutical nanocarriers

Lee

Yeo

2015

Chemical Engineering Science

420

240

View full text Add to dashboard Cite

show abstract

“…One of the focuses of the anticancer investigations is a search for effective antitumor drugs by inhibition of tumor cell proliferation, metabolism, and metastatic activity [14, 15]. Doxorubicin is one of such inhibitors [16–19]. Doxorubicin is an anthracycline drug which was extracted from Streptomyces peucetius var.…”

Section: Introductionmentioning

confidence: 99%

Functionalization of Carbon Nanomaterial Surface by Doxorubicin and Antibodies to Tumor Markers

Perepelytsina¹,

Yakymchuk²,

Sydorenko³

et al. 2016

Nanoscale Res Lett

View full text Add to dashboard Cite

The actual task of oncology is effective treatment of cancer while causing a minimum harm to the patient. The appearance of polymer nanomaterials and technologies launched new applications and approaches of delivery and release of anticancer drugs. The goal of work was to test ultra dispersed diamonds (UDDs) and onion-like carbon (OLCs) as new vehicles for delivery of antitumor drug (doxorubicin (DOX)) and specific antibodies to tumor receptors. Stable compounds of UDDs and OLCs with DOX were obtained. As results of work, an effectiveness of functionalization was 2.94 % w/w for OLC-DOX and 2.98 % w/w for UDD-DOX. Also, there was demonstrated that UDD-DOX and OLC-DOX constructs had dose-dependent cytotoxic effect on tumor cells in the presence of trypsin. The survival of adenocarcinoma cells reduced from 52 to 28 % in case of incubation with the UDD-DOX in concentrations from 8.4–2.5 to 670–20 μg/ml and from 72 to 30 % after incubation with OLC-DOX. Simultaneously, antibodies to epidermal growth factor maintained 75 % of the functional activity and specificity after matrix-assisted pulsed laser evaporation deposition. Thus, the conclusion has been made about the prospects of selected new methods and approaches for creating an antitumor agent with capabilities targeted delivery of drugs.

show abstract

“…The azo-linkers could be selectively recognized and cleaved via an NADPH-dependent mechanism using azoreductase enzymes present in the cytoplasm of hepatic cancer cells. This approach could be successfully explored for controlled delivery of drugs to hepatic cancer cells [82]. …”

Section: Dendrimers As An Emerging Vista In Anticancer Therapymentioning

confidence: 99%

Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery

Kesharwani

Iyer

2015

Drug Discovery Today

329

136

View full text Add to dashboard Cite

Advances in the application of nanotechnology in medicine have given rise to multifunctional smart nanocarriers that can be engineered with tunable physicochemical characteristics to deliver one or more therapeutic agent(s) safely and selectively to cancer cells, including intracellular organelle-specific targeting. Dendrimers having properties resembling biomolecules, with well-defined 3D nanopolymeric architectures, are emerging as a highly attractive class of drug and gene delivery vector. The presence of numerous peripheral functional groups on hyperbranched dendrimers affords efficient conjugation of targeting ligands and biomarkers that can recognize and bind to receptors overexpressed on cancer cells for tumor-cell-specific delivery. The present review compiles the recent advances in dendrimer-mediated drug and gene delivery to tumors by passive and active targeting principles with illustrative examples.

show abstract

Enzyme-activated nanoconjugates for tunable release of doxorubicin in hepatic cancer cells

Cited by 82 publications

References 51 publications

Controlled drug release from pharmaceutical nanocarriers

Controlled drug release from pharmaceutical nanocarriers

Functionalization of Carbon Nanomaterial Surface by Doxorubicin and Antibodies to Tumor Markers

Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery

Contact Info

Product

Resources

About